COMPOSITION OF AYURVEDIC SWARNA BHASMA AS A POTENTIAL VACCINE ADJUVANT AGAINST INTRACELLULAR PATHOGENS

Abstract

This invention provides an Ayurvedic-based vaccine adjuvant using Swarna Bhasma, aimed at enhancing immune response and supporting vaccine efficacy. The formulation promotes balanced Th1, Th2, and Th17 responses, extending immune memory, and reducing reliance on synthetic adjuvants. The adjuvant demonstrates efficacy in preclinical studies, indicating its potential as a natural, cost-effective alternative for sustainable vaccine development.

Specification

Description:FIELD OF THE INVENTION
This invention relates to vaccine development and immunology, specifically focusing on the use of Ayurvedic Swarna Bhasma as an adjuvant to enhance immune response against intracellular pathogens. The formulation aims to leverage Swarna Bhasma's immunostimulatory properties to support vaccine efficacy, offering an alternative to synthetic adjuvants in vaccine preparations.
BACKGROUND OF THE INVENTION
Vaccines have been one of the most effective means of preventing infectious diseases. However, developing vaccines against intracellular pathogens like tuberculosis, malaria, and HIV remains challenging due to immune evasion and inadequate immunological memory. Adjuvants, which enhance immune responses to antigens, are critical in vaccine formulations. Most conventional adjuvants, such as aluminum salts, stimulate humoral immunity but lack the capability to induce a balanced Th1/Th2/Th17 response necessary for intracellular pathogens. This invention addresses these limitations by exploring Swarna Bhasma, a traditional Ayurvedic preparation known for its immunostimulatory effects, as a natural adjuvant. This approach seeks to modulate immune responses in a way that supports both immediate and long-term immunity, reducing dependency on synthetic adjuvants and enhancing vaccine efficacy for intracellular infections.
SUMMARY OF THE INVENTION
This summary is provided to introduce a selection of concepts, in a simplified format, that are further described in the detailed description of the invention.
This summary is neither intended to identify key or essential inventive concepts of the invention and nor is it intended for determining the scope of the invention.
To further clarify advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof, which is illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail with the accompanying drawings.
The invention provides an adjuvant formulation based on Ayurvedic Swarna Bhasma, designed to boost immune response in vaccine applications targeting intracellular pathogens. The Swarna Bhasma formulation aims to generate balanced Th1, Th2, and Th17 immune responses, facilitating enhanced immune memory and providing prolonged protection. By incorporating Swarna Bhasma into vaccine formulations, the invention offers an alternative adjuvant option that is natural, cost-effective, and potentially less toxic compared to synthetic adjuvants, thereby supporting sustainable and accessible vaccine development.
DETAILED DESCRIPTION OF THE INVENTION
The detailed description of various exemplary embodiments of the disclosure is described herein with reference to the accompanying drawings. It should be noted that the embodiments are described herein in such details as to clearly communicate the disclosure. However, the amount of details provided herein is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the scope of the present disclosure as defined by the appended claims.
It is also to be understood that various arrangements may be devised that, although not explicitly described or shown herein, embody the principles of the present disclosure. Moreover, all statements herein reciting principles, aspects, and embodiments of the present disclosure, as well as specific examples, are intended to encompass equivalents thereof.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments. As used herein, the singular forms "a"," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises," "comprising," "includes" and/or "including," when used herein, specify the presence of stated features, integers, steps, operations, elements and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups thereof.
It should also be noted that in some alternative implementations, the functions/acts noted may occur out of the order noted in the figures. For example, two figures shown in succession may, in fact, be executed concurrently or may sometimes be executed in the reverse order, depending upon the functionality/acts involved.
In addition, the descriptions of "first", "second", "third", and the like in the present invention are used for the purpose of description only, and are not to be construed as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Thus, features defining "first" and "second" may include at least one of the features, either explicitly or implicitly.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which example embodiments belong. It will be further understood that terms, e.g., those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
The composition of Swarna Bhasma as an adjuvant is developed to enhance immune response in vaccines targeting intracellular pathogens. Swarna Bhasma, traditionally used in Ayurvedic medicine, is a finely prepared gold ash with known immunomodulatory effects. Its particle size and purity are controlled through repeated calcination processes, resulting in a composition that can interact efficiently with immune cells. The formulation process begins with the purification of raw gold, followed by calcination in herbal extracts to yield Swarna Bhasma with specific physicochemical properties. These properties are essential for inducing a targeted immune response and are confirmed through chemical characterization techniques, including particle size analysis and surface morphology studies.
The adjuvant potential of Swarna Bhasma is evaluated both in vitro and in vivo. In vitro studies involve assessing cytokine production by immune cells exposed to Swarna Bhasma, with a focus on key indicators of Th1, Th2, and Th17 responses. These cytokines indicate the ability of Swarna Bhasma to balance humoral and cellular immunity, critical for combating intracellular pathogens. In vivo studies are conducted using animal models, where the Swarna Bhasma-based adjuvant is administered with specific vaccine antigens. The results demonstrate enhanced antibody production, increased T-cell memory, and longer-lasting immune responses compared to traditional adjuvants, indicating the potential of Swarna Bhasma as a robust vaccine adjuvant.
Swarna Bhasma's role as an adjuvant is further assessed by comparing its immune-enhancing effects with conventional adjuvants like aluminum salts. The comparison shows that Swarna Bhasma induces a broader range of immune responses, effectively bridging gaps in conventional adjuvant performance. These findings support the use of Swarna Bhasma as a sustainable, cost-effective alternative for vaccines, particularly those targeting intracellular pathogens where comprehensive immune activation is essential. The adjuvant formulation is positioned to reduce the need for synthetic adjuvants, lowering production costs and expanding accessibility to effective vaccines worldwide.
, Claims:1. An Ayurvedic-based vaccine adjuvant formulation comprising Swarna Bhasma, designed to enhance immune response in vaccines targeting intracellular pathogens.
2. The adjuvant as claimed in Claim 1, wherein the Swarna Bhasma is prepared through calcination to achieve particle sizes that optimize immune cell interaction.
3. The adjuvant as claimed in Claim 1, wherein the formulation induces a balanced Th1, Th2, and Th17 immune response, promoting long-term immunity and memory cell formation.
4. The adjuvant as claimed in Claim 1, wherein in vitro and in vivo studies demonstrate superior cytokine induction and immune memory development compared to traditional adjuvants.
5. The adjuvant as claimed in Claim 1, wherein it provides a natural and cost-effective alternative to synthetic adjuvants, supporting sustainable vaccine development.
6. A method of enhancing immune response in vaccines as claimed in Claim 1, involving the use of Swarna Bhasma to augment cellular and humoral immunity.
7. The adjuvant as claimed in Claim 1, wherein the formulation demonstrates efficacy in generating immune responses against intracellular pathogens, reducing the dependency on chemically synthesized adjuvants.

Documents